3月5日 - ** 生物制药公司Halozyme Therapeutics HALO.O股价上涨2.7%至59.70美元
** 据《华尔街日报》报导，默克公司MRK.N的抗癌大片Keytruda注射剂可能面临来自Halozyme的潜在专利挑战 (link)。
** 报导称，哈洛认为新版Keytruda侵犯了其专利权
** 注射版 Keytruda 仍在临床测试中，预计将于 2026 年初推出
** 股价在过去 12 个月上涨了 42
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.